시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 희귀 피부 질환 치료 시장 보고서(2025년)
Rare Dermatological Disease Treatment Global Market Report 2025
상품코드 : 1855964
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,700,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,685,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,669,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

희귀 피부 질환 치료 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 52억 4,000만 달러로 평가되었고, 2025년에는 55억 7,000만 달러에 달하고, CAGR 6.4%로 성장할 전망입니다. 이 기간의 성장은 환자 의식 증가, 희귀질환 유병률 증가, 특수 요법 채택 확대, 병원 및 클리닉 인프라 성장, 건강 관리 지출 증가로 이어집니다.

희귀 피부 질환 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.2%로 70억 8,000만 달러로 성장할 전망입니다. 예측기간의 성장은 맞춤형 의료에 대한 수요 증가, 디지털 헬스 기술 채택 확대, 특수 의약품 투자 확대, 원격 의료 서비스 확대, 환자 중심 케어 중점화 등을 뒷받침하고 있습니다. 이 기간의 주요 동향에는 기술 진보, 표적 생물 제제 개발, 연구 개발 투자 증가, 저분자 억제제 혁신, 고급 치료제 진보 등이 포함됩니다.

희귀 피부과 질환의 유병률 증가는 희귀 피부 질환 치료 시장의 성장을 가속할 것으로 예측됩니다. 표피 수포증, 페프리구스 불가리스, 피부 홍반성 루푸스 등의 질병은 인구의 극히 일부를 앓고 있지만 전문적인 치료와 표적 요법이 필요합니다. 유전자 검사의 진보, 질병에 대한 의식의 높아짐, 조기 진단에 의해 세계적으로 사례 수가 증가하고 있습니다. 이러한 인식은 유전자 치료, 선진 생물 제제, 지지 요법 솔루션 등 증상 관리, 상처 치유 촉진, 환자 결과 개선을 목적으로 하는 혁신적인 치료에 대한 수요를 증가시키고 있습니다. 예를 들어, 2025년 1월 CDC는 이영양성 표피 수포증에 대한 재사용 가능한 유전자 치료제인 Vyjuvek(beremagene geperpavec-svdt)이 임상시험에서 상처의 상당한 폐쇄를 나타내며 혁신적인 치료법의 잠재력을 강조했다고 보고했습니다. 그 결과, 희소 피부 질환 증가가 희귀 피부 질환 치료 시장의 성장에 크게 기여하고 있습니다.

희귀 피부 질환 치료 시장의 주요 기업은 환자의 예후를 개선하고 치료 요법을 단순화하고 삶의 질을 높이기 위해 재사용 가능한 유전자 치료와 같은 고급 유전자 치료의 개발에 주력하고 있습니다. 이런 유형의 치료는 기능적인 COL7A1 유전자를 환부의 피부에 직접 투여하여 반복적이고 비 침습적으로 적용하여 단백질 기능을 회복시키고 상처 치유를 촉진하고 조직 수복을 가속화 할 수 있습니다. 예를 들어, 2023년 5월 미국 생명공학 기업인 크리스탈 바이오테크(Krystal Biotech)는 이영양성 표피 수포증 치료제로 Vyjuvek(beremagene geperpavec-svdt)를 발표했습니다. 임상시험에서 24주 시점의 상처 완전 봉합율은 위약이 26%인 반면 Vyjuvek은 65%였습니다. Vyjuvek는 특정 상처에 대해 일주일에 한 번 비침습 치료 옵션을 제공하여 수술의 필요성을 줄입니다. 또한 효능을 유지하기 위해 특별한 콜드체인 보관이 필요하지만 비 침습적인 클리닉 투여 솔루션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Rare dermatological disease treatment refers to medical approaches aimed at diagnosing and managing uncommon skin disorders. These treatments are specialized due to the rarity and complexity of the conditions. They include targeted therapies, supportive care, and continuous monitoring to control symptoms and maintain skin health.

The primary indication types in rare dermatological disease treatment include systemic sclerosis, epidermolysis bullosa, pemphigus vulgaris, and cutaneous lupus erythematosus. Systemic sclerosis is a rare condition that can cause hardening of the skin and connective tissues. In some cases, it is visible on the face, hands, feet, and other areas as the skin thickens and firms. Treatments for systemic sclerosis focus on managing skin fibrosis and vascular complications and include corticosteroids, immunosuppressants, anti-inflammatory agents, and other therapies, which are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Technologies applied in these treatments include gene therapy, stem cell therapy, and nanotechnology, which are also used for epidermolysis bullosa, ichthyosis, psoriasis, and other rare skin conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The rare dermatological disease treatment market research report is one of a series of new reports from The Business Research Company that provides rare dermatological disease treatment market statistics, including rare dermatological disease treatment industry global market size, regional shares, competitors with the rare dermatological disease treatment market share, rare dermatological disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the rare dermatological disease treatment industry. This rare dermatological disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare dermatological disease treatment market size has grown strongly in recent years. It will grow from $5.24 billion in 2024 to $5.57 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period is driven by increasing patient awareness, rising prevalence of rare diseases, expanding adoption of specialized therapies, growth of hospital and clinic infrastructure, and higher healthcare expenditure.

The rare dermatological disease treatment market size is expected to see strong growth in the next few years. It will grow to $7.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The projected growth in the forecast period is supported by rising demand for personalized medicine, greater adoption of digital health technologies, increased investment in specialty drugs, expansion of telemedicine services, and a stronger focus on patient-centric care. Key trends in this period include technological advancements, development of targeted biologics, growth in research and development investment, innovations in small molecule inhibitors, and progress in advanced therapeutics.

The increasing prevalence of rare dermatological conditions is expected to drive the growth of the rare dermatological disease treatment market. Disorders such as epidermolysis bullosa, pemphigus vulgaris, and cutaneous lupus erythematosus affect a small portion of the population but demand specialized care and targeted therapies. Advances in genetic testing, heightened disease awareness, and earlier diagnoses have led to a growing number of cases being identified globally. This recognition has created a rising demand for innovative treatments such as gene therapies, advanced biologics, and supportive care solutions, which are aimed at managing symptoms, enhancing wound healing, and improving patient outcomes. For example, in January 2025, the CDC reported that Vyjuvek (beremagene geperpavec-svdt), a redosable gene therapy for dystrophic epidermolysis bullosa, showed substantial wound closure in clinical trials, underlining the potential of innovative therapies. As a result, the growing number of rare skin conditions is significantly contributing to the growth of the rare dermatological disease treatment market.

Leading companies in the rare dermatological disease treatment market are focusing on the development of advanced gene therapies, such as redosable gene therapy, to improve patient outcomes, simplify treatment regimens, and enhance quality of life. This type of therapy delivers functional COL7A1 genes directly to the affected skin, allowing repeated, non-invasive applications that restore protein function, promote wound healing, and expedite tissue repair. For instance, in May 2023, Krystal Biotech, a US-based biotechnology company, introduced Vyjuvek (beremagene geperpavec-svdt) for the treatment of dystrophic epidermolysis bullosa. In clinical studies, the therapy achieved a 65% complete wound closure rate at 24 weeks compared to 26% with a placebo. Vyjuvek offers a once-weekly, non-invasive treatment option for specific wounds, reducing the need for surgery. It also provides a non-invasive clinic-administered solution while requiring specialized cold-chain storage to maintain its effectiveness.

In March 2025, Scinai Immunotherapeutics, an Israel-based provider of immunology biologics and contract development services, acquired Pincell srl for an undisclosed amount. This acquisition allows Scinai to expand its immunology portfolio and strengthen its position in the rare dermatological space. Through this deal, Scinai gained access to PC111, a monoclonal antibody in development for conditions such as pemphigus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Pincell srl, an Italy-based company, specializes in biologic therapies for severe and rare dermatological disorders.

Major players in the rare dermatological disease treatment market are Kyowa Kirin, Johnson and Johnson company, F. Hoffmann-La Roche Limited, Merck KGaA, Arcutis Biotherapeutics, Pfizer Inc., Abbvie, Sanofi, Novartis AG, AstraZeneca, Eli lilly and company, Amgen, Bristol Myers Squibb Company, Pierre Fabre Laboratories, LEO Pharma, Almirall, Castle Creek Biosciences, Inc., Azitra, Krystal Biotech, Inc., Avita Medical, NS Pharma, Replay, Eloxx Pharmaceuticals, Kamari Pharma, BPGbio.

North America was the largest region in the personalized genomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare dermatological disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare dermatological disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare dermatological disease treatment market includes revenues earned by entities by genetic counseling and testing, specialized histopathology, multidisciplinary clinical consultations, patient registry management, and custom-compounded topical formulations. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare dermatological disease treatment market consists of sales of orphan drugs, targeted biologic therapies, advanced topical immune modulators, novel small molecule inhibitors, and specialized wound care and protective dressings. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Dermatological Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare dermatological disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for rare dermatological disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare dermatological disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Rare Dermatological Disease Treatment Market Characteristics

3. Rare Dermatological Disease Treatment Market Trends And Strategies

4. Rare Dermatological Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rare Dermatological Disease Treatment Growth Analysis And Strategic Analysis Framework

6. Rare Dermatological Disease Treatment Market Segmentation

7. Rare Dermatological Disease Treatment Market Regional And Country Analysis

8. Asia-Pacific Rare Dermatological Disease Treatment Market

9. China Rare Dermatological Disease Treatment Market

10. India Rare Dermatological Disease Treatment Market

11. Japan Rare Dermatological Disease Treatment Market

12. Australia Rare Dermatological Disease Treatment Market

13. Indonesia Rare Dermatological Disease Treatment Market

14. South Korea Rare Dermatological Disease Treatment Market

15. Western Europe Rare Dermatological Disease Treatment Market

16. UK Rare Dermatological Disease Treatment Market

17. Germany Rare Dermatological Disease Treatment Market

18. France Rare Dermatological Disease Treatment Market

19. Italy Rare Dermatological Disease Treatment Market

20. Spain Rare Dermatological Disease Treatment Market

21. Eastern Europe Rare Dermatological Disease Treatment Market

22. Russia Rare Dermatological Disease Treatment Market

23. North America Rare Dermatological Disease Treatment Market

24. USA Rare Dermatological Disease Treatment Market

25. Canada Rare Dermatological Disease Treatment Market

26. South America Rare Dermatological Disease Treatment Market

27. Brazil Rare Dermatological Disease Treatment Market

28. Middle East Rare Dermatological Disease Treatment Market

29. Africa Rare Dermatological Disease Treatment Market

30. Rare Dermatological Disease Treatment Market Competitive Landscape And Company Profiles

31. Rare Dermatological Disease Treatment Market Other Major And Innovative Companies

32. Global Rare Dermatological Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Dermatological Disease Treatment Market

34. Recent Developments In The Rare Dermatological Disease Treatment Market

35. Rare Dermatological Disease Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기